Non-Hodgkin Lymphoma | Topics

Early Intrathecal Therapy Appears Feasible, Efficacious for ICANS in R/R B-cell Non-Hodgkin Lymphoma
May 12, 2022

Patients with relapsed/refractory B-cell non-Hodgkin lymphoma who experienced grade 3 or higher immune effector cell–associated neurotoxicity syndrome who were treated with early intrathecal therapy experienced improved survival.

ZUMA-5 Data Indicate Response and Efficacy With Axi-Cel in Indolent Non-Hodgkin Lymphoma at 2-Year Follow-Up
April 25, 2022

The use of axicabtagene ciloleucel for relapse/refractory indolent non-Hodgkin lymphoma continued the duration of response during the follow-up of the phase 2 ZUMA-5 trial.

Younger Vs Older B-Cell NHL Survivors Show Increased Risk of Adverse Health Outcomes
February 27, 2022

Younger survivors of B-cell non-Hodgkin lymphoma appeared to have an increased risk of adverse health outcomes 5 or more years after diagnosis compared with older survivors.

No Improvement in EFS for Aggressive B-cell NHL Noted With Second-line Tisagenlecleucel
December 13, 2021

Patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma did not benefit in terms of event-free survival when treated with the CAR T-cell therapy tisagenlecleucel vs standard-of-care chemotherapy and transplant.

Examining Social Inequity and Racial Disparities in T-Cell Lymphoma
October 14, 2021

As treatment for T-cell non-Hodgkin lymphomas continues to expand, disparities and inequities continue to grow for those within certain racial groups and of a certain socioeconomic status.

Emergency Fertility Preservation in a Young Woman With Non-Hodgkin Lymphoma
June 19, 2021

A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.

Regardless of Prior Anti-CD20 Therapy, Axi-Cel induces Durable Antitumor Activity in FL and MZL
June 15, 2021

CAR T-cell therapy with axicabtagene ciloleucel (axi-cel; Yescarta) showed promise in patients with high-risk relapsed/refractory indolent non-Hodgkin lymphoma.

CAR T-Cell Therapy, C-CAR066, Showed Promising Efficacy in R/R B-NHL
June 08, 2021

CAR066, showed a favorable safety profile and promising efficacy in the treatment of adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed prior CD19 CAR T-cell therapy.

Odronextamab Shows Promise in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
December 06, 2020

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Combined HDAC, mTOR Inhibition Shows Clinical Efficacy in Relapsed/Refractory Hodgkin Lymphoma
October 15, 2020

This phase 1 study found that vorinostat (Zolinza) in combination with either sirolimus (Rapamune) or everolimus (Afinitor) demonstrated clinical efficacy in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.